Rapid Dose Therapeutics Corp (RDTCF) Stock Statistics & Valuation Metrics
Total Valuation
Rapid Dose Therapeutics Corp has a market cap or net worth of $10.24M. The enterprise value is $21.70M.
- Market Cap
- $10.24M
- Enterprise Value
- $21.70M
Share Statistics
Rapid Dose Therapeutics Corp has 137,782,930 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 137,782,930
- Owned by Insiders
- 9.57%
- Owned by Institutions
- ―
Financial Efficiency
Rapid Dose Therapeutics Corp’s return on equity (ROE) is 0.47 and return on invested capital (ROIC) is 117.10%.
- Return on Equity (ROE)
- 0.47
- Return on Assets (ROA)
- -1.03
- Return on Invested Capital (ROIC)
- 117.10%
- Return on Capital Employed (ROCE)
- 0.42
- Revenue Per Employee
- 231.11K
- Profits Per Employee
- -282.47K
- Employee Count
- 12
- Asset Turnover
- 0.84
- Inventory Turnover
- 23.29
Valuation Ratios
The current PE Ratio of Rapid Dose Therapeutics Corp is -4.04. Rapid Dose Therapeutics Corp’s PEG ratio is -0.07.
- PE Ratio
- -4.04
- PS Ratio
- 6.18
- PB Ratio
- -1.58
- Price to FCF
- 31.30
- Price to Operating Cash Flow
- 30.84
- PEG Ratio
- -0.07
Income Statement
In the last 12 months, Rapid Dose Therapeutics Corp had revenue of 2.77M and earned -3.39M in profits. Earnings per share was -0.03.
- Revenue
- 2.77M
- Gross Profit
- -956.89K
- Operating Income
- -2.17M
- Pretax Income
- -3.39M
- Net Income
- -3.39M
- EBITDA
- -1.66M
- Earnings Per Share (EPS)
- -0.03
Cash Flow
In the last 12 months, operating cash flow was 419.09K and capital expenditures -904, giving a free cash flow of 418.18K billion.
- Operating Cash Flow
- 419.09K
- Free Cash Flow
- 418.18K
- Free Cash Flow per Share
- 0.00
Dividends & Yields
Rapid Dose Therapeutics Corp pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 3.19%
- Earnings Yield
- -24.31%
Stock Price Statistics
- Beta
- 0.20
- 52-Week Price Change
- -52.00%
- 50-Day Moving Average
- 0.08
- 200-Day Moving Average
- 0.08
- Relative Strength Index (RSI)
- 49.10
- Average Volume (3m)
- 22.85K
Important Dates
Rapid Dose Therapeutics Corp upcoming earnings date is Feb 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Oct 30, 2026
- Next Earnings Date
- Feb 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Rapid Dose Therapeutics Corp as a current ratio of 0.04, with Debt / Equity ratio of -74.16%
- Current Ratio
- 0.04
- Quick Ratio
- 0.02
- Debt to Market Cap
- 0.15
- Net Debt to EBITDA
- -3.20
- Interest Coverage Ratio
- -1.78
Taxes
In the past 12 months, Rapid Dose Therapeutics Corp has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Rapid Dose Therapeutics Corp EV to EBITDA ratio is -13.27, with an EV/FCF ratio of 44.15.
- EV to Sales
- 8.71
- EV to EBITDA
- -13.27
- EV to Free Cash Flow
- 44.15
- EV to Operating Cash Flow
- 44.05
Balance Sheet
Rapid Dose Therapeutics Corp has $8,625.00 in cash and marketable securities with $5.38M in debt, giving a net cash position of -$5.37M billion.
- Cash & Marketable Securities
- $8,625.00
- Total Debt
- $5.38M
- Net Cash
- -$5.37M
- Net Cash Per Share
- -$0.04
- Tangible Book Value Per Share
- -$0.06
Margins
Gross margin is -46.88%, with operating margin of -88.50%, and net profit margin of -148.27%.
- Gross Margin
- -46.88%
- Operating Margin
- -88.50%
- Pretax Margin
- -148.27%
- Net Profit Margin
- -148.27%
- EBITDA Margin
- -65.67%
- EBIT Margin
- -88.50%
Analyst Forecast
The average price target for Rapid Dose Therapeutics Corp is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -18.50%
- EPS Growth Forecast
- 34.12%
